Simultaneous inhibition of TGF-β2-TGFβR and RTK signaling in HNSCC yields greater anti-tumor effects relative to blockade of either alone (Figs 3–5). The gene discussed is TGFB2; the disease is head and neck squamous cell carcinoma.